Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 9 recruiting now early-phase tilt

HIV Infection: early-phase trial registry

9 of 74 indexed HIV Infection trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #183 of 28,707 conditions by registered trial count.

74 US clinical trials · 9 currently recruiting · #183 of 28,707 conditions by registered trial count

HIV Infection: 74 US clinical trials tracked, 9 recruiting.

HIV Infection is the subject of 74 registered US clinical trials on ClinicalTrials.gov, 9 of them currently open to new participants. 15 are in Phase 3-4 (later-stage) and 32 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Allergy and Infectious Diseases (NIAID), running 12 of these trials.

Enrollment posture brief

Registry condition hiv-infection

OPEN 9 | RECR 12% | LATE 15 | EARLY 32 | RANK #183 | SPON 12

Nearest open-share peer: Hepatitis C (12% recruiting · 108 trials)

Chronic Kidney Diseases62.2%Anatomic Stage II Breast Can54.1%Chronic Myelomonocytic Leuke40.5%Anemia18.9%HIV Infection (this)12%
Open-enrollment share among volume-matched conditions near HIV Infection

HIV Infection lists 9 open slots (12% of 74 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for HIV Infection on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. HIV Infection is recruiting below its size-band peers.

    9 of 74 indexed trials (12.2%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates HIV Infection research.

    National Institute of Allergy and Infectious Diseases (NIAID) accounts for 12 of 74 trials (16.2%). 40 distinct sponsors appear on at least one study for this condition label.

  3. Most HIV Infection trials plan to enrol fewer than 100 people.

    Median target enrolment is 55 among the 74 trials that report a genuine target (sentinel values excluded). 48 of those (64.9%) plan for fewer than 100 participants.

  4. HIV Infection research is mostly interventional.

    57 interventional and 17 observational studies make up this index (77% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 120Phase 212Phase 38Phase 47

Open and recent trials

74 total, page 2 of 2

COMPLETED Phase 1 42 participants

Use of Combined Antiretroviral Therapy to Determine Sites of Persistent HIV Infection

National Institute of Allergy and Infectious Diseases (NIAID)

NCT00001644

COMPLETED Phase 1 41 participants

A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ABBV-181 (Budigalimab) in Adult Participants With Human Immunodeficiency Virus (HIV)-1

AbbVie

NCT04223804

COMPLETED Phase 2 40 participants

The Role of Ampligen in Strategic Therapeutic Intervention (STI) of HAART

AIM ImmunoTech

NCT00035893

COMPLETED 38 participants

Immune and Viral Status of HIV-Infected Patients After Stopping Combination Antiretroviral Therapy

National Institute of Allergy and Infectious Diseases (NIAID)

NCT00001899

COMPLETED 38 participants

Evaluation of Barriers to Postpartum Care in HIV Infected Women

The University of Texas Health Science Center, Houston

NCT01853917

COMPLETED Phase 1 36 participants

Cabozantinib S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus

National Cancer Institute (NCI)

NCT01822522

COMPLETED Phase 4 36 participants

Boosted Lexiva With Lovaza Adjunctive Therapy in Hypertriglyceridemic, HIV-Infected Subjects

Felizarta, Franco, M.D.

NCT01010399

COMPLETED 36 participants

Influence of Antiretroviral Regimen on Immune Reconstitution in the Female Genital Tract

University of Colorado, Denver

NCT01456962

COMPLETED Phase 2 36 participants

Pharmacodynamics of Intermittent IL-2 Infusions in HIV Seropositive Patients

National Institute of Allergy and Infectious Diseases (NIAID)

NCT00001474

COMPLETED Phase 1 31 participants

Phase I Protocol for the Evaluation of the Safety and Immunogenicity of Vaccination With Synthetic HIV Envelope Peptides in Patients With Early Human Immunodeficiency Virus Infection

National Cancer Institute (NCI)

NCT00001386

COMPLETED 30 participants

Physiologic Investigation of the Renin Angiotensin Aldosterone Axis in HIV

Massachusetts General Hospital

NCT01407237

COMPLETED Phase 1 29 participants

Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01), Administered Intravenously or Subcutaneously to Healthy Adults

National Institute of Allergy and Infectious Diseases (NIAID)

NCT01993706

COMPLETED Phase 2 28 participants

Therapeutic Intensification Plus Immunomodulation to Decrease the HIV-1 Viral Reservoir

Robert L. Murphy

NCT00976404

COMPLETED NA 25 participants

Androgen Effects in HIV-infected Women

Massachusetts General Hospital

NCT00095212

COMPLETED Phase 2 25 participants

Continued Antiretroviral Therapy With Abacavir, Amprenavir and Efavirenz

National Institute of Allergy and Infectious Diseases (NIAID)

NCT00001758

COMPLETED NA 24 participants

Technology-based Training Tool for PHAT Life

Oregon Research Behavioral Intervention Strategies

NCT05339412

COMPLETED Phase 1 20 participants

Pharmacokinetics of Antiretroviral Agents in HIV-1 Infected Pregnant Women

National Institute of Allergy and Infectious Diseases (NIAID)

NCT00006320

COMPLETED Phase 1 20 participants

The Effect of Milk Thistle on the Pharmacokinetics of Indinavir

National Institutes of Health Clinical Center (CC)

NCT00011635

COMPLETED Phase 1 19 participants

Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients

Sangamo Therapeutics

NCT01044654

COMPLETED Phase 1 18 participants

Evaluation of the Safety of a Polyvalent Virus in Healthy Adults

St. Jude Children's Research Hospital

NCT00187044

COMPLETED Phase 1 17 participants

Reducing the Residual Reservoir of HIV-1 Infected Cells in Patients Receiving Antiretroviral Therapy

Massachusetts General Hospital

NCT02471430

COMPLETED 12 participants

SNAP: Switching Nucleoside Analogues Protocol - Lipoatrophy and Mitochondrial Function

Northwestern University

NCT00225082

COMPLETED NA 7 participants

Immune Activation and Drug Absorption in HIV-Infected Patients

Drexel University

NCT01845298

COMPLETED 2 participants

IMPAACT P1107: Effects of Cord Blood Transplantation With CCR5Δ32 Donor Cells on HIV Persistence

International Maternal Pediatric Adolescent AIDS Clinical Trials Group

NCT02140944

← Previous Page 2 of 2

Phase Distribution

PhaseTrial count
Phase 1 20
Phase 2 12
Phase 3 8
Phase 4 7

Named interventions

Most-linked intervention names on HIV Infection records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Laboratory Biomarker Analysis Other
3 trials
Atazanavir Drug
2 trials
DOR/ISL Drug
2 trials
Interleukin-2 Drug
2 trials
Etoposide Drug
2 trials
Colonoscopy Procedure
2 trials
Computed Tomography Procedure
2 trials
Biospecimen Collection Procedure
2 trials

US sites by state

Facility locations filed on HIV Infection trials. A trial with sites in several states counts in each.

California 33 trials
Maryland 26 trials
New York 25 trials
Florida 20 trials
Illinois 18 trials
Massachusetts 12 trials
Texas 11 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this HIV Infection page

74 registered trials, 9 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This HIV Infection condition card totals 74 registered trials; most-linked intervention Laboratory Biomarker Analysis; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.